Moneycontrol PRO
HomeNewsBusinessStocksCipla up 3% on collaboration with Teva for South Africa

Cipla up 3% on collaboration with Teva for South Africa

The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa, says the company in its filing.

October 09, 2014 / 14:45 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Moneycontrol Bureau

    Shares of Cipla gained as much as 3.3 percent on Thursday after its subsidiary Medpro Pharmaceutica entered into collaboration with Teva Pharmaceuticals for South African market.

    Medpro Pharmaceutica is a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa. Cipla, in 2013, bought out Cipla Medpro completely for Rs 2,707 crore. Teva is the largest generic pharmaceutical manufacturer in the world.

    The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa, says the company in its filing, adding the collaboration will focus on oncology, central nervous system, women's health, cardiovascular, ophthalmology and other specialty products.

    The collaboration is subject to approval by the Competition Commission of South Africa. At 10:43 hours IST, the stock was quoting at Rs 598.05, up Rs 12.75, or 2.18 percent on the BSE.

    Posted by Sunil Shankar Matkar

    first published: Oct 9, 2014 10:44 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347